At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 101 enrolled
Drug / intervention
temsirolimus +1 moredrug
Likely dose
temsirolimus 175mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
In Brief
A Phase 4 clinical trial evaluating temsirolimus for Non-Hodgkin's Lymphoma. Completed, enrolled 101 participants across 31 sites in 11 countries.
Detailed Summary
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesAustralia, Czechia, France, Germany, Italy, Poland, Romania, Russia, Serbia, South Korea, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartMar 2011
Primary CompletionNov 2015
Study CompletionJun 2018
TodayJul 2026
First PostedAug 11, 2010
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2015
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 15.9 years ago
Interventions
temsirolimusdrug
175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
temsirolimusdrug
75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit